While observational studies demonstrate that statin use is associated with reduced cancer-specific mortality in patients with mCRPC receiving ADT (153), the results from one randomized trial indicates that short-term statin use does not impact tumor proliferation or serum prostate-specific antigen (PSA) compared to placebo (154). This evidence concerns the gene KLK3 and neoplasm.